Relying excessively on the market's evaluation of companies through their share prices in the short-term is a one-way ticket to the poorhouse.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025